Thymosin Alpha-1
The Immune-Balancing Peptide
Thymosin alpha-1 is a small, precisely defined peptide your own thymus gland makes a version of, and it does something unusual: it helps steady an immune system that has drifted in either direction, calming one that is overactive and waking up one that is falling behind.
It is one of the peptides we reach for most on the immune side of our practice.
.svg)
What we have seen in practice
Thymosin alpha-1 is Dr. Koniver's favorite immune-modulating peptide, and he does not hedge about it: in his experience it may be the most potent immune-modulating compound there is. What makes it stand out is that it works in both directions. It can help settle an immune system that has turned on itself, as in autoimmune disease, and it can help lift one that has grown sluggish, the kind of immune system that keeps getting knocked down by colds, infections, and viruses. Very few compounds do both.
Much of our experience is on the autoimmune side. Dr. Koniver has watched inflammatory markers in autoimmune patients settle right down on thymosin alpha-1, and we use it across conditions like Hashimoto's, celiac, Crohn's, ulcerative colitis, and lupus. He points out how common this problem is: more people are walking around with autoimmune disease than with heart disease and cancer combined, and women carry that burden about four times as often as men. The other half of our experience is post-viral. Thymosin alpha-1 was one of the tools we relied on heavily through the pandemic to help people get their immune systems back to normal after an illness, and Dr. Koniver treats that ability to restore immune balance as its defining strength.
We use it a few ways. Most often it is a subcutaneous injection, and because it is so well tolerated it is an easy peptide to start with; Dr. Koniver often suggests it first when someone is not sure where to begin. When we want to move faster, we also give it intravenously, added to a drip as a spark to get the immune system going.
Thymosin alpha-1 at a glance
A lab-made peptide, 28 amino acids long, copying the most active immune fragment of a natural thymus-gland protein
.svg)
Immune balance and restoration: viral infection (including hepatitis and COVID), immune support during cancer care, and age-related immune decline
.svg)
Decades of approved clinical use outside the US plus real human studies, including a COVID mortality study; much of the wider literature is reviews rather than large new trials [1, 2]
.svg)
Usually by subcutaneous injection; also intravenously in our immune IV work
.svg)
28 amino acids, formula C129H215N33O55, about 3,108 g/mol, N-terminally acetylated [5]
Not FDA-approved in the US and caught in the US compounding review; approved and used in about 35 countries; not named by WADA. Details below
Our go-to immune-modulating peptide, for both overactive and underactive immune systems. See what we have seen in practice above
Pink bead = the acetylated N-terminus (Ac-Ser). All 28 residues shown; none of them carry sulfur.
Thymosin alpha-1's real formula is C129H215N33O55. It contains none of the two sulfur-carrying amino acids, so any formula printed with a sulfur atom - including the one on the reference page we worked from - is describing a different molecule. Its 28-amino-acid sequence is fixed and known; the shortened, altered sequence that gets copied around does not match the real peptide. We state the correct chemistry because precision is the whole point of a molecule this specific.
Where thymosin alpha-1 comes from
The starting point is an organ most people forget they have. The thymus is a small gland behind the breastbone that acts as the training school for T-cells, a core part of the immune system, early in life. It does most of its work when we are young and then slowly shrinks with age, which is one reason immune function tends to fade over the decades.
Thymosin alpha-1 was found inside that gland. In the 1970s, researchers purifying a thymic extract identified it as one of the most active immune-signaling pieces, then reproduced it synthetically so it could be made to a consistent standard. That synthetic version, known generically as thymalfasin, is what is studied and used today. It is the same short peptide the thymus itself contributes, which is part of why it reads to the body as a familiar signal rather than a foreign drug.
How thymosin alpha-1 works
It supports the maturation of T-cells and sharpens the activity of natural killer cells, which clear infected and abnormal cells - restoring the coordination the thymus provided more readily when we were younger. [2, 4]
.svg)
Rather than simply pushing the immune system up, it steadies the cytokine mix: raising helpful signals when a response is too weak and restraining excess inflammatory signals when a response runs too hot. This is the mechanism behind the both-directions point. [2, 4]
.svg)
By improving how immune cells recognize and clear viruses, it has long been studied as a way to strengthen the body's own defenses against viral infection rather than attacking the virus directly. [1, 2]
Autoimmune
Rebalances
Frequent infection
The same peptide can settle an immune system that is too active and strengthen one that is falling behind.
Much of the wider literature is review articles rather than large new trials - we cite those as reviews.
What the research shows
Thymosin alpha-1 sits in an unusual place: it has more genuine human history than almost any research peptide, because it has been an approved medicine outside the United States for decades, yet a good deal of the recent literature is review articles rather than fresh large trials. We try to be precise about which is which.
The most concrete outcome evidence comes from viral illness. In a study of severe COVID-19, thymosin alpha-1 was associated with reduced mortality and with restoration of the depleted lymphocyte counts that mark serious infection, an effect consistent with what the peptide is understood to do. That built on a much longer track record in chronic hepatitis B, where thymalfasin has been an approved, used treatment in many countries for years. Alongside these, the peptide has been studied as support during cancer care and for the immune decline that comes with age.
We also want to be honest about the shape of the evidence. Some widely cited summaries, including the reference we worked from, group together large patient totals under a single heading; when we traced those, they came from review articles pulling many small studies together rather than from one large trial. The reviews are real and worth citing, and we do, but we name them as reviews. What we can stand behind most firmly is the approved international use in hepatitis, the COVID mortality study, and decades of a well-characterized safety record.
Severe viral infection (COVID-19) [1]
A human clinical study
Reduced mortality; restored lymphocyte counts
Real human outcome data
Chronic hepatitis B
Decades of approved international use
Established immune-support role in approved settings
Approved medicine outside the US
Cancer-care immune support [3]
Clinical studies and reviews
Reported benefit as an adjunct
Described, mostly reviews
Age-related immune decline
Smaller studies and reviews
Improved immune markers and vaccine response
Suggestive, needs larger trials
Immune balance in our patients
Clinical experience
Autoimmune and post-viral immune modulation
Clinical observation (our practice)
How strong is the evidence
Real human history where it is strongest, honest labels where it is thinner. Words only, no scores.
Thymosin alpha-1 has one of the calmer safety records in this directory, backed by decades of clinical use in the countries where it is approved. Reactions tend to be mild: some soreness at the injection site, occasionally a short-lived tired or flu-like feeling, and rarely an allergic reaction. There is no signal for major organ toxicity, and Dr. Koniver's own experience matches the literature, he does not recall a patient having a real problem with it.
A few sensible cautions apply. Because it acts on the immune system, there is a reasonable theoretical note about using it when the immune system is already highly active; in practice thymosin alpha-1 is used to balance autoimmune conditions rather than simply stimulate them, but that work belongs under physician supervision and monitoring. We avoid it in pregnancy and breastfeeding for lack of data, and it deserves care alongside immune-suppressing medicines. As with any peptide that reaches the wellness market largely through compounding and research channels, quality and sourcing genuinely matter.
Regulatory status around the world
Regulatory information current as of 13 August 2026. This is a summary, not legal or medical advice, and status can change.
Internationally
APPROVED ABROAD
As thymalfasin, it is an approved, marketed medicine in roughly 35 countries, used for indications such as chronic hepatitis B and as an immune adjuvant. That real approval abroad is a meaningful part of why the peptide is taken seriously.
Sport (WADA)
NOT NAMED · VERIFY
Not named on the Prohibited List. It is a different molecule from thymosin beta-4 (the peptide behind TB-500), which the List does name by name. Because thymosin alpha-1 lacks broad approval, the catch-all category for non-approved substances could apply where it is unapproved - athletes should verify with their governing body.
United States
UNDER REVIEW · NOT APPROVED
Not FDA-approved. Nominated for the compounding list and placed in the more restricted Category 2; an FDA advisory committee reviewed it in December 2024 and did not recommend adding it to the approved compounding list. Its status through 2026 is reported inconsistently between sources - verify the current position.
Everywhere else
VARIES BY COUNTRY
Prescription rules differ; thymosin alpha-1 is approved in some regions and not others, and products sold outside licensed channels carry the quality risks described in the safety section.
Regulatory information current as of 13 August 2026.
Thymosin alpha-1, answered plainly
It is a lab-made peptide, 28 amino acids long, copying the most active immune fragment of a natural protein made by the thymus gland. It is used to balance and support the immune system.
Because it modulates rather than simply stimulates. Thymosin alpha-1 helps steady the immune signaling network, which means it can calm a response that is overactive and strengthen one that is underactive. Dr. Koniver considers that two-way balancing its defining feature.
No. It is not approved in the United States and reached the wellness market through compounding, and its US compounding status has been under restriction and review. It is, however, an approved medicine in roughly 35 other countries. The regulatory section above has the detail.
Both come from the thymus and both support the immune system, and we use them together. The difference is what they are: thymosin alpha-1 is a single, precisely defined synthetic peptide, while thymalin is an extract, a mixture of thymic peptides. They are partners in purpose, not the same kind of molecule.
Related Peptides in this directory
References
- Liu Y, Pang Y, Hu Z, et al. Thymosin Alpha 1 Reduces the Mortality of Severe Coronavirus Disease 2019 by Restoration of Lymphocytopenia and Reversion of Exhausted T Cells. Clin Infect Dis. 2020;71(16):2150-2157. PMID 32442287.
- Tao N, Xu X, Ying Y, et al. Thymosin alpha1 and Its Role in Viral Infectious Diseases: The Mechanism and Clinical Application. Molecules. 2023;28(8):3539. PMID 37110771.
- Dominari A, Hathaway Iii D, Pandav K, et al. Thymosin alpha 1: A comprehensive review of the literature. World J Virol. 2020;9(5):67-78. PMID 33362999.
- Garaci E. Thymosin alpha1: a historical overview. Ann N Y Acad Sci. 2007;1112:14-20. PMID 17567941.
- Molecular data: thymosin alpha-1 (thymalfasin), PubChem CID 16130571, formula C129H215N33O55, molecular weight ~3108.3 g/mol; sequence Ac-SDAAVDTSSEITTKDLKEKKEVVEEAEN (no sulfur-containing residues). Regulatory sources: FDA Pharmacy Compounding Advisory Committee materials (December 2024); international marketing status of thymalfasin (ZADAXIN). Verify current US compounding status at publication.
This page is for informational and educational purposes and does not constitute medical advice, diagnosis, or treatment. Thymosin alpha-1 is not approved by the FDA for any use in the United States and is available only through research and compounding channels; it is an approved medicine in a number of other countries. Statements describing how Dr. Koniver and the Koniver Wellness team use thymosin alpha-1 reflect clinical experience and judgment, which is not the same as controlled clinical evidence. Nothing here is a substitute for consultation with a qualified healthcare provider. Peptide therapy at Koniver Wellness is provided under physician supervision after appropriate screening, and the availability of any given peptide depends on its regulatory and supply status. Regulatory information is current as of the date shown and may have changed; verify with official sources or a licensed practitioner in your jurisdiction.
INTERESTED IN PEPTIDES?
START WITH THE RIGHT QUESTIONS.
Understand what peptides can and cannot do, what the evidence actually says, and whether physician-guided peptide therapy makes sense for you.